Last $51.88 USD
Change Today +0.34 / 0.66%
Volume 5.6M
WFC On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
Bogota
As of 1:27 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
McClatchy-Tribune  06/09/2014 12:01 AM ET
VBL Therapeutics files for $75m Nasdaq IPO [Globes, Tel Aviv, Israel :: ]

June 09--On Friday, VBL Therapeutics Ltd. (formerly Vascular Biogenics) published a draft prospectus with the US Securities and Exchange Commission (SEC) to raise up to $75 million, including the underwriters' over-allotment option, on Nasdaq. The drug development company did not disclose the company value for the offering.

The underwriters are Deutsche Bank Securities LLC, Wells Fargo, JPMorgan, and Oppenheimer.

VBL is developing drugs for the treatment of cancer and inflammatory diseases. It was founded in 2000 and has raised more than $100 million to date. None of its products have yet been commercialized, and it has no revenue. The company has $10 million in cash. Its investors include US insurer Keffi Group and real estate developer Jechezkiel Gonczarowski. VBL founder and CEO Prof. Dror Harats. Other shareholders are Pitango Venture Capital, Aurum Ventures MKI, GlenRock Israel, Kadima High Tech, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), and private investors.

VBL initially developed treatment for deep vein thrombosis, a cause of strokes and heart attacks, but decided that this was beyond its capabilities as a start-up. The company is currently developing a treatment for brain cancer, for which it hopes to hopes to begin a Phase III clinical trial in 2015, and has other drugs in the pipeline.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WFC:US $51.88 USD +0.34

Industry News

Bay Commercial Bank Reports Second Quarter 2014 Results

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WELLS FARGO & CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.